Controlled Substances Program
The Controlled Substances Program (CSP) is overseen by the Deputy Center Director for Substance Use and Behavioral Health and aims to promote the public health by minimizing risks associated with problematic use of controlled substances while enabling appropriate access for medical use.
CSP’s core functions include:
- Proactively identifying and analyzing emerging issues with controlled substances and related strategies and initiatives that could help drive appropriate access
- Providing technical expertise on drug assessment and scheduling, and consultation services for specific drug applications
- Serving to coordinate and support CDER’s work on controlled substance policies and programs with internal and external stakeholders
- Communicating with external stakeholders, including other government agencies, industry, and academia, on emerging issues and ongoing initiatives and policies at FDA around controlled substances
CSP comprises the Controlled Substance Staff (CSS), a group focused on the assessment of the abuse potential of drugs; and Controlled Substances Initiatives (CSI), a group focused on proactive activities and policies to identify, mitigate, and manage emerging issues with controlled substances.
More information on Controlled Substance Staff.
Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health, Office of the Center Director
Conference Grant Applications
PAR-23-072 - FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed) Grant Applications
The Center for Drug Evaluation and Research (CDER) is currently accepting applications to support the organization of public conferences under the Controlled Substances Program (CSP). CDER/CSP is interested in applications that propose one or more workshops to address topics including, but not limited to the following:
- Adults with attention-deficit/hyperactivity disorder (ADHD): considerations for diagnosis and treatment
- Root causes, perceptions, and consequences of non-medical use of prescription stimulants including overdosage and toxicity
- Emerging substances with abuse potential
- Developments regarding psychedelics for therapeutic use
For more information, please visit the funding opportunity announcement.